Detalhe da pesquisa
1.
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
J Transl Med
; 22(1): 326, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38566102
2.
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
BMC Med
; 20(1): 197, 2022 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644609
3.
Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases.
J Transl Med
; 20(1): 74, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123506
4.
Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data.
Future Oncol
; 16(31): 2569-2586, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32927981
5.
Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases.
Int J Clin Oncol
; 25(2): 267-273, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31587134
6.
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
BMC Cancer
; 18(1): 1171, 2018 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30477470
7.
Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospital.
Support Care Cancer
; 24(4): 1763-9, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26441076
8.
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.
Oncoimmunology
; 13(1): 2340154, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38601319
9.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Sci Bull (Beijing)
; 69(4): 535-543, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185589
10.
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
J Thorac Oncol
; 19(4): 601-612, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981218
11.
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.
Cancers (Basel)
; 15(1)2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36612298
12.
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
Ther Adv Med Oncol
; 15: 17588359231167818, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113733
13.
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Mol Oncol
; 17(8): 1581-1594, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078460
14.
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Signal Transduct Target Ther
; 8(1): 442, 2023 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057314
15.
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.
Cell Rep
; 42(7): 112797, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37436890
16.
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Cancer Cell
; 41(10): 1763-1773.e4, 2023 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37816331
17.
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Nat Med
; 29(8): 2079-2086, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488286
18.
Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score.
Transl Oncol
; 15(1): 101254, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715621
19.
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.
Thorac Cancer
; 13(11): 1619-1630, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35437920
20.
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Front Immunol
; 13: 951817, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263036